Kestra Medical CBO awarded 39,113 shares

Kestra Medical Technologies, Ltd. executive Timothy P. Moran, Chief Business Officer, reported an acquisition of 39,113 common shares.

Rhea-AI Filing Summary

Kestra Medical Technologies, Ltd. executive Timothy P. Moran, Chief Business Officer, reported an acquisition of 39,113 common shares. These shares were earned from a July 17, 2025 grant of performance-based RSUs ("PSUs") that vested 100% on July 15, 2026 after specified performance goals were achieved. The PSUs settled at a reported price of $0.0000 per share, increasing Moran’s direct holdings to 81,601 common shares. The transaction was coded as a grant/award acquisition, not a market purchase or sale, and was not indicated as being under a Rule 10b5-1 trading plan.

Insider Trade Summary

Grant/Award: 39,113 shares

Grant/Award 1 txn

Insider Moran Timothy P.

Role Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares F1	39,113	$0.00	$0.00

Holdings After Transaction: Common Shares — 81,601 shares (Direct)

Footnotes (1)

1. F1. Represents common shares earned with respect to an award of performance-based RSUs ("PSUs") granted on July 17, 2025, as determined based on the Issuer's achievement of specified performance goals. 100% of the PSUs vested on July 15, 2026.

Key Figures

Shares acquired: 39,113 common shares Price per share: $0.0000 per share Total holdings after: 81,601 common shares +3 more

6 metrics

Shares acquired 39,113 common shares Grant/award acquisition of common shares reported on 2026-07-16

Price per share $0.0000 per share Settlement price for shares delivered from vested PSUs

Total holdings after 81,601 common shares Direct ownership following the reported acquisition

PSU grant date July 17, 2025 Date the performance-based RSUs underlying this award were granted

PSU vesting date July 15, 2026 Date when 100% of the performance-based RSUs vested

Transaction date July 16, 2026 Date of the reported Form 4 acquisition of common shares

Key Terms

performance-based RSUs, PSUs, vested, Chief Business Officer

4 terms

performance-based RSUs financial

"Represents common shares earned with respect to an award of performance-based RSUs ("PSUs")"

Performance-based restricted stock units (RSUs) are promises to deliver company shares to employees only if the business meets specific goals, such as revenue, profit, stock-price targets, or strategic milestones. For investors, they matter because they change future share supply and align management incentives with company results—like a salesperson whose bonus only pays out when sales targets are hit—so they can affect earnings, dilution, and confidence in leadership.

PSUs financial

"an award of performance-based RSUs ("PSUs") granted on July 17, 2025"

PSUs are company shares promised to employees or executives that only become actual stock if the business hits specific performance targets over a set period. For investors, PSUs matter because they link pay to measurable outcomes — similar to a conditional bonus that converts into ownership — which can influence management decisions, dilution of shares, and signals about confidence in future results.

vested financial

"100% of the PSUs vested on July 15, 2026"

Chief Business Officer financial

"Moran Timothy P. serves as Chief Business Officer"

A chief business officer (CBO) is the executive responsible for a company's commercial strategy, partnerships, licensing, and business development—essentially the leader who turns technology or products into paying customers and deals. Investors care because the CBO's choices about partnerships, pricing, market entry and revenue models directly influence how fast a company grows and how much future cash flow or value it can deliver; think of the CBO as the company's head coach for winning business and income.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kestra Medical (KMTS) executive Timothy P. Moran report?

Timothy P. Moran reported an acquisition of 39,113 Kestra Medical common shares. The shares came from performance-based RSUs that fully vested after the company achieved specified performance goals, and were reported as a grant/award rather than an open-market trade.

How many Kestra Medical (KMTS) shares did Moran acquire and at what price?

Moran acquired 39,113 common shares of Kestra Medical at a reported price of $0.0000 per share. The zero price reflects settlement of vested performance-based RSUs, not a cash purchase in the open market.

What RSU award led to Timothy P. Moran’s new Kestra Medical (KMTS) shares?

The shares were earned from a performance-based RSU ("PSU") award granted on July 17, 2025. According to the disclosure, 100% of the PSUs vested on July 15, 2026 based on Kestra Medical’s achievement of specified performance goals.

What is Timothy P. Moran’s Kestra Medical (KMTS) shareholding after this Form 4 transaction?

Following the reported award, Moran directly holds 81,601 Kestra Medical common shares. This figure represents his direct ownership after adding the 39,113 shares delivered upon vesting of the performance-based RSUs described in the filing.

Was Moran’s Kestra Medical (KMTS) Form 4 transaction under a Rule 10b5-1 trading plan?

The filing indicates the transaction was not effected under a Rule 10b5-1 trading plan. The document-level 10b5-1 checkbox is marked false, and the footnotes do not state that a pre-arranged trading plan governed this equity award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 05:52 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moran Timothy P.

(Last) (First) (Middle)

3933 LAKE WASHINGTON BLVD NE

SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	07/16/2026		A		39,113(1)	A	$0	81,601	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents common shares earned with respect to an award of performance-based RSUs ("PSUs") granted on July 17, 2025, as determined based on the Issuer's achievement of specified performance goals. 100% of the PSUs vested on July 15, 2026.

	/s/ Traci S. Umberger as attorney-in-fact for Timothy P. Moran	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)